Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2004 4
2005 1
2006 1
2007 1
2008 2
2009 4
2010 7
2011 3
2012 3
2013 5
2014 8
2015 17
2016 19
2017 10
2018 17
2019 20
2020 15
2021 21
2022 33
2023 28
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Results by year

Filters applied: . Clear all
Page 1
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Pu X, Xiao Z, Li J, Wu Z, Ma Z, Weng J, Xiao M, Chen Y, Cao Y, Cao P, Wang Q, Xu Y, Li K, Chen B, Xu F, Liu L, Kong Y, Zhang H, Duan H, Wu L. Pu X, et al. Among authors: kong y. Lung Cancer. 2024 Mar 18;191:107538. doi: 10.1016/j.lungcan.2024.107538. Online ahead of print. Lung Cancer. 2024. PMID: 38552544 Free article.
Assessing the precision of AI in ED triage decisions.
Zhu H, Kong Y. Zhu H, et al. Among authors: kong y. Am J Emerg Med. 2024 May;79:214. doi: 10.1016/j.ajem.2024.02.035. Epub 2024 Feb 28. Am J Emerg Med. 2024. PMID: 38458951 No abstract available.
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
Pu X, Lin G, Xiao M, Lin J, Wang Q, Kong Y, Yan X, Xu F, Xu Y, Li J, Li K, Chen B, Wen X, Tan Y, Cheng F, Zhu K, Li N, Wu L. Pu X, et al. Among authors: kong y. EClinicalMedicine. 2024 Jan 3;67:102403. doi: 10.1016/j.eclinm.2023.102403. eCollection 2024 Jan. EClinicalMedicine. 2024. PMID: 38261958 Free PMC article.
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Chen B, Yao W, Li X, Lin G, Chu Q, Liu H, Du Y, Lin J, Duan H, Wang H, Xiao Z, Sun H, Liu L, Xu L, Xu Y, Xu F, Kong Y, Pu X, Li K, Wang Q, Li J, Li B, Xia Y, Wu L. Chen B, et al. Among authors: kong y. Br J Cancer. 2024 Feb;130(3):450-456. doi: 10.1038/s41416-023-02519-0. Epub 2023 Dec 18. Br J Cancer. 2024. PMID: 38110665 Clinical Trial.
203 results